Table 4.
Adverse and serious adverse events up to 6 months of observation
| Most reported adverse events (AEs) n (%) | N = 99 | 
|---|---|
| Constipation | 21 (21.2) | 
| Insufficient effect | 6 (6.1) | 
| Lack of efficacy | 6 (6.1) | 
| Diarrhea | 5 (5.1) | 
| Injection site reaction | 2 (2.0) | 
| Serious adverse events (SAEs) n (%) | 12 (12.1) | 
| Anaphylactic shocka | 1 (1.0) | 
| Chest pain and arm pain left side | 1 (1.0) | 
| COVID-19 | 1 (1.0) | 
| Inpatient headache therapy | 2 (2.0) | 
| Kidney stone | 1 (1.0) | 
| Medication overuse headache needing withdrawal in hospital setting | 1 (1.0) | 
| Meningioma | 1 (1.0) | 
| Mycoplasma pneumonia | 1 (1.0) | 
| Right motor and sensory syndrome and migraine | 1 (1.0) | 
| Transitory ischemic attack | 1 (1.0) | 
| Urinary tract infection | 1 (1.0) | 
aFour months after erenumab discontinuation, hence no causal relationship assumed
Abbreviations: AE Adverse event, SAE Serious adverse event